SCHEMBL24848921

SCHEMBL24848921

CC(C)(C)CCNc1ccc(-c2ccccc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.43
▸ MAPT P10636 2/20 0.43
▸ FNTA P49354 1/20 0.42
▸ FNTB P49356 1/20 0.42
▸ HIF1A Q16665 1/20 0.42
▸ HTT P42858 2/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ MITF O75030 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ FFAR1 O14842 3/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ FFAR4 Q5NUL3 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ KIF11 P52732 1/20 0.38
▸ SLC6A2 P23975 1/20 0.37
▸ MMP12 P39900 1/20 0.37
▸ MMP13 P45452 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4762870 0.88 MAPT (0.56) ALDH1A1MAPTHIF1AHTTRAB9A
SCHEMBL12932873 0.80 GHSR (0.46) ALDH1A1MAPTFNTAFNTBHTT
SCHEMBL5308535 0.78 MAPT (0.43) ALDH1A1MAPTHTTNPC1RAB9A
SCHEMBL8260133 0.78 ALDH1A1 (0.48) ALDH1A1MAPTFNTAFNTBHTT
SCHEMBL13167595 0.76 HRH3 (0.49) MAPTHTTNPC1RAB9ASMN1; SMN2
SCHEMBL21800004 0.76 APP (0.44) ALDH1A1MAPTHTTRAB9AMEN1
SCHEMBL8972279 0.74 ALDH1A1 (0.56) ALDH1A1MAPTFNTAFNTBNPC1
SCHEMBL10250638 0.74 MLYCD (0.47) ALDH1A1MAPTFNTAFNTBMITF
SCHEMBL24023612 0.74 SMN1; SMN2 (0.56) ALDH1A1MAPTHTTRAB9ASMN1; SMN2
SCHEMBL5471155 0.74 MAPT (0.38) ALDH1A1MAPTHIF1AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230020663-A1 SULFONAMIDE INHIBITORS AS CTPS1 INHIBITORS STEP PHARMA S.A.S. (FR) 2023-01-19 — — US disclosed
US-20230002352-A1 SULFONAMIDE DERIVATIVES AS CTPS1 INHIBITORS STEP PHARMA S.A.S. (FR) 2023-01-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230020663-A1 SULFONAMIDE INHIBITORS AS CTPS1 INHIBITORS CTPS1, CTPS2, TYMS ALDH1A1 1517/4885MAPT 4424/4885FNTA 1682/4885
US-20230002352-A1 SULFONAMIDE DERIVATIVES AS CTPS1 INHIBITORS CTPS1, CTPS2, TYMS ALDH1A1 978/4885MAPT 4588/4885FNTA 1657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback